News | August 02, 2013

Mercator Gains Patent for Micro-Infusion Drug Delivery for Renal Denervation

Mercator’s Micro-Infusion devices treat peripheral artery disease (PAD), other cardiovascular diseases and pulmonary disease, and deliver of stem cells

August 2, 2013 — Mercator MedSystems has been issued U.S. Patent 8,465,752, which protects the company’s sole U.S. rights to deliver drugs or other nerve modifying agents to tissue surrounding arteries for renal denervation (RDN). The system also can be used for carotid body modulation (CBM) procedures. 

These procedures, used to modulate or deaden hyperactive nerves, are designed to decrease uncontrolled hypertension, or high blood pressure, and are believed to be effective alternative therapies for the more than 12 million patients worldwide whose blood pressure remains uncontrolled – even with the use of three or more anti-hypertensive medications.

Mercator’s Micro-Infusion devices are currently used for treating peripheral artery disease (PAD), other cardiovascular diseases and pulmonary disease, and for the delivery of stem cells.

Mercator recently completed a clinical feasibility study at St. Catherine’s Hospital in Frankfurt, Germany to determine the effectiveness of lidocaine delivery, prior to energy-based renal denervation, as a means of alleviating or minimizing pain experienced with these procedures. Ablating or cauterizing the nerves lining the renal arteries with radio-frequency or ultrasound-equipped catheters often produces intense pain that is difficult to control – even with the use of systemic painkillers and morphine.  Four patients were pre-treated with promising results. 

After the procedures, one of St. Catherine’s treating physicians, Horst Sievert commented said, “I am impressed with the ease of delivery and the interactive visualization offered by Mercator’s Bullfrog Micro-Infusion device. While there is more work to be done, this appears to be a promising approach as a pre-treatment – and longer term, with a neuro-modulating drug, as an alternative approach to RDN.”

Mercator’s Bullfrog and Cricket Micro-Infusion devices are cleared for commercialization in Europe, the United States and Australia.  The Micro-Infusion approach was created in the labs of The University of California, Berkeley in 2000.

For more information: www.mercatormed.com

Related Content

USC Study Finds Potassium-Rich Diet Can Lower Blood Pressure
News | Hypertension| April 19, 2017
Eating potassium-rich foods like sweet potatoes, avocados, spinach, beans, bananas and even coffee could be key to...
Vascular Dynamics Completes $10.4 Million Financing for MobiusHD System
News | Hypertension| April 13, 2017
Vascular Dynamics Inc. (VDI) a privately held medical device company developing novel solutions for the treatment of...
online lifestyle intervention, systolic blood pressure, hypertension, ACC.17, clinical study
News | Hypertension| March 27, 2017
Participants in Web-based lifestyle counseling reduced their systolic blood pressure by 10 mmHg, compared with a 6 mmHg...
News | Hypertension| February 13, 2017
Vascular Dynamics Inc. (VDI) announced that the U.S. Food and Drug Administration (FDA) has approved the company’s...
blood pressure, gray zone, hypertension, personalized treatment, Circulation journal study, CT calcium scores
News | Hypertension| January 23, 2017
Using data from a national study, Johns Hopkins researchers determined that using heart computed tomography (CT) scans...
Suntech Medical, Oscar 2 ambulatory blood pressure monitoring system, ABPM, Patient Diary App, SphygmoCor Inside
Technology | Blood Pressure Monitor| January 17, 2017
The new SunTech Oscar 2 24-hour ambulatory blood pressure monitoring system is now available with the True24 ABPM...
Sponsored Content | Videos | Hypertension| November 08, 2016
Krishna Rocha-Singh, M.D., Prairie Vascular Institute, Springfield, Ill., explains advancements in device therapy for
white coat hypertension, heart disease risk, blood pressure spike, doctor's office, Journal of the American College of Cardiology, JACC study
News | Hypertension| October 31, 2016
White coat hypertension, where patients have high blood pressure readings in a medical setting but normal blood...
News | Renal Denervation| October 11, 2016
Awards from the National Institutes of Health’s Common Fund are supporting research on the peripheral nervous system,...
Technavio report, renal denervation devices, 2015
News | Renal Denervation| August 23, 2016
August 23, 2016 — Technavio analysts forecast the global...
Overlay Init